Nautilus Biotechnology Stock Price To Sales

NAUT Stock

USD 2.40 0.02 0.84%

Nautilus Biotechnology fundamentals help investors to digest information that contributes to Nautilus Biotechnology's financial success or failures. It also enables traders to predict the movement of Nautilus Stock. The fundamental analysis module provides a way to measure Nautilus Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nautilus Biotechnology stock.

Last Reported

Projected for Next Year

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Nautilus Biotechnology Company Price To Sales Analysis

Nautilus Biotechnology's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Nautilus Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for Nautilus Biotechnology is extremely important. It helps to project a fair market value of Nautilus Stock properly, considering its historical fundamentals such as Price To Sales. Since Nautilus Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nautilus Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nautilus Biotechnology's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Short Term Investments	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Accounts Payable	Property Plant Equipment	Current Deferred Revenue	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Capital Stock	Net Working Capital	Short Term Debt
Total Assets		0.94	-0.71	-0.7	-0.44	-0.45	0.87	0.89	0.87	0.89	0.35	-0.19	0.9	-0.31	0.92	0.9	0.87	0.61
Total Stockholder Equity	0.94		-0.46	-0.8	-0.69	-0.73	0.94	0.98	0.94	0.96	0.44	-0.25	0.97	-0.37	0.98	0.97	0.91	0.68
Net Debt	-0.71	-0.46		0.2	-0.01	-0.19	-0.52	-0.4	-0.39	-0.45	-0.29	-0.14	-0.41	-0.05	-0.47	-0.41	-0.52	-0.11
Retained Earnings	-0.7	-0.8	0.2		0.76	0.71	-0.73	-0.88	-0.93	-0.88	-0.67	0.68	-0.91	0.79	-0.86	-0.92	-0.68	-0.92
Short Term Investments	-0.44	-0.69	-0.01	0.76		0.91	-0.76	-0.76	-0.73	-0.75	-0.77	0.33	-0.73	0.45	-0.73	-0.73	-0.65	-0.58
Total Liab	-0.45	-0.73	-0.19	0.71	0.91		-0.71	-0.76	-0.73	-0.73	-0.45	0.31	-0.73	0.41	-0.74	-0.74	-0.66	-0.57
Total Current Assets	0.87	0.94	-0.52	-0.73	-0.76	-0.71		0.92	0.89	0.95	0.57	-0.05	0.9	-0.34	0.94	0.9	0.97	0.54
Common Stock	0.89	0.98	-0.4	-0.88	-0.76	-0.76	0.92		0.96	0.98	0.57	-0.38	0.99	-0.45	0.98	0.99	0.86	0.8
Net Tangible Assets	0.87	0.94	-0.39	-0.93	-0.73	-0.73	0.89	0.96		0.97	0.53	-0.43	0.97	-0.65	0.98	0.99	0.89	0.79
Accounts Payable	0.89	0.96	-0.45	-0.88	-0.75	-0.73	0.95	0.98	0.97		0.59	-0.3	0.98	-0.51	0.98	0.98	0.91	0.77
Property Plant Equipment	0.35	0.44	-0.29	-0.67	-0.77	-0.45	0.57	0.57	0.53	0.59		-0.43	0.55	-0.42	0.52	0.56	0.39	0.56
Current Deferred Revenue	-0.19	-0.25	-0.14	0.68	0.33	0.31	-0.05	-0.38	-0.43	-0.3	-0.43		-0.43	0.62	-0.32	-0.44	0.02	-0.75
Capital Surpluse	0.9	0.97	-0.41	-0.91	-0.73	-0.73	0.9	0.99	0.97	0.98	0.55	-0.43		-0.52	0.98	1.0	0.85	0.83
Deferred Long Term Liab	-0.31	-0.37	-0.05	0.79	0.45	0.41	-0.34	-0.45	-0.65	-0.51	-0.42	0.62	-0.52		-0.5	-0.57	-0.4	-0.67
Net Invested Capital	0.92	0.98	-0.47	-0.86	-0.73	-0.74	0.94	0.98	0.98	0.98	0.52	-0.32	0.98	-0.5		0.99	0.93	0.71
Capital Stock	0.9	0.97	-0.41	-0.92	-0.73	-0.74	0.9	0.99	0.99	0.98	0.56	-0.44	1.0	-0.57	0.99		0.87	0.82
Net Working Capital	0.87	0.91	-0.52	-0.68	-0.65	-0.66	0.97	0.86	0.89	0.91	0.39	0.02	0.85	-0.4	0.93	0.87		0.46
Short Term Debt	0.61	0.68	-0.11	-0.92	-0.58	-0.57	0.54	0.8	0.79	0.77	0.56	-0.75	0.83	-0.67	0.71	0.82	0.46

Click cells to compare fundamentals

The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Competition

Predict Nautilus Biotechnology

Price To Sales Ratio Over Time

Based on the latest financial disclosure, Nautilus Biotechnology has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to sales for all United States stocks is 100.0% higher than that of the company.

Nautilus Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nautilus Biotechnology's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nautilus Biotechnology could also be used in its relative valuation, which is a method of valuing Nautilus Biotechnology by comparing valuation metrics of similar companies.

Nautilus Biotechnology is currently under evaluation in price to sales category among its peers.

Nautilus Biotechnology ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Nautilus Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Nautilus Biotechnology's managers, analysts, and investors.

Environmental

Governance

Social

Nautilus Fundamentals

	Return On Equity	-0.28
	Return On Asset	-0.18
	Current Valuation	192.31 M
	Shares Outstanding	125.56 M
	Shares Owned By Insiders	33.46 %
	Shares Owned By Institutions	50.22 %
	Number Of Shares Shorted	1.21 M
	Price To Book	1.35 X
	EBITDA	(74.3 M)
	Net Income	(63.67 M)
	Cash And Equivalents	299.34 M
	Cash Per Share	2.40 X
	Total Debt	34.63 M
	Debt To Equity	0.09 %
	Current Ratio	49.75 X
	Book Value Per Share	1.78 X
	Cash Flow From Operations	(51.71 M)
	Short Ratio	19.69 X
	Earnings Per Share	(0.56) X
	Target Price	3.56
	Number Of Employees	161
	Beta	1.04
	Market Capitalization	301.35 M
	Total Asset	305.56 M
	Retained Earnings	(202.24 M)
	Working Capital	167.72 M
	Net Asset	305.56 M

About Nautilus Biotechnology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Nautilus Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nautilus Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nautilus Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC